Verona Pharma plc
VRNA
Rang în acțiuni
#2227
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Preț acțiune
$106.91
Ultima sincronizare: 2025-10-07
Capitalizare de piață
$9.09B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
GB
Tranzacționează Verona Pharma plc (VRNA)
Categorie
Healthcare
EPS pentru Verona Pharma plc (VRNA)
EPS la data de June 2025 TTM: $-0.77
Conform celor mai recente rapoarte financiare și prețului acțiunilor Verona Pharma plc, EPS-ul actual al companiei (TTM) este $-0.77. La sfârșitul anului 2023, compania avea un EPS de $-0.54 o scădere comparativ cu EPS-ului din 2022, care a fost de $-0.86.
Istoricul EPS pentru Verona Pharma plc din 2005 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-0.77 | -54.71% |
| 2024 | $-1.70 | 214.81% |
| 2023 | $-0.54 | -37.21% |
| 2022 | $-0.86 | 24.64% |
| 2021 | $-0.69 | -52.41% |
| 2020 | $-1.45 | -53.07% |
| 2019 | $-3.09 | 60.65% |
| 2018 | $-1.92 | -23.89% |
| 2017 | $-2.53 | 70.63% |
| 2016 | $-1.48 | -66.16% |
| 2015 | $-4.38 | 121.20% |
| 2014 | $-1.98 | -59.64% |
| 2013 | $-4.90 | 43.91% |
| 2012 | $-3.41 | -36.19% |
| 2011 | $-5.34 | -10.68% |
| 2010 | $-5.98 | 9.91% |
| 2009 | $-5.44 | 41.09% |
| 2008 | $-3.85 | -38.00% |
| 2007 | $-6.22 | 108.58% |
| 2006 | $-2.98 | -3,065.67% |
| 2005 | $0.10 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -2,349.35% |
US
|
|
| $-7.98 | 936.36% |
US
|
|
| $-5.29 | 587.01% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,702.60% |
NL
|
